Novo Nordisk shares dropped 2.5% after Deutsche Bank's weekly prescription data tracker indicated a continued slowdown in the oral version of its weight-loss drug, Wegovy, in the US. This slowdown is significant because the oral formulation was seen as a key growth driver, and rivals are developing their own oral weight-loss treatments. While Ozempic showed double-digit upside, the bank expects single-digit downside for the Wegovy pill and double-digit downside for the injectable Wegovy SC and Rybelsus for the 2026 financial year.
UBS has reiterated its overweight stance on European pharmaceuticals, viewing the sector as a more stable investment than artificial intelligence amid a slowing market. The bank highlights improving earnings, low valuations, and lighter ownership as ...
The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical c...
Novo Nordisk is rated a BUY as its oral Wegovy drug rapidly expands the obesity treatment market in the U.S., with over 3 million prescriptions in five months, mostly from patients new to GLP-1 treatments. This strong demand has led management to rai...
